A Landmark Decision: Appeals Court Upholds Ban on Overseas Drug Imports by Funding Programs

Well, here's some big news that could truly reshape a corner of the pharmaceutical world. A federal appeals court just came down with a significant decision, upholding an earlier order that blocks certain companies from bringing Gilead Sciences' vital HIV medication, Biktarvy, into the U.S. from overseas. This isn't just a technical legal ruling; it’s a robust affirmation of how crucial it is to keep our drug supply chain secure and, frankly, safe for patients.

The ruling, handed down by the U.S. Court of Appeals for the Fourth Circuit on August 13, 2026, really zeroed in on the practice of Alternative Funding Programs, or AFPs, which have been importing these drugs. Companies like Rx Valet, Meritain Health (a CVS Health's Aetna subsidiary, mind you), and Pro-Act, a pharmacy benefits manager, were all named as defendants. The court basically said, "Hold on a minute, there's a difference here, and it's not a small one."

At the heart of the matter is Biktarvy itself. While the drug sold in Turkey – where the specific imported medication originated in a case that sparked this whole lawsuit – might share the same chemical formula as its U.S. counterpart, the court found them to be "materially, not theoretically" different. What does that even mean? It comes down to safety, quality control systems, and the entire supply chain. You see, when a drug comes through unauthorized foreign channels, it bypasses the stringent oversight that the FDA and manufacturers like Gilead put in place. This isn't just about a label; it's about the entire journey of that medicine from factory to patient.

Gilead Sciences, the manufacturer, initially filed this lawsuit back in December 2024. The whole thing kicked off after a patient in Maryland received Turkish-labeled Biktarvy, directly imported via one of these AFPs. It raised immediate red flags about the integrity and safety of the medication reaching patients. A U.S. District Court in Maryland subsequently awarded a preliminary injunction to Gilead in June 2025, a decision now firmly backed by the appeals court.

Phil Blando, a spokesperson for Aetna, weighed in, expressing disappointment with the ruling and stating that "Meritain will explore its legal options." It’s clear this decision sends ripples through the industry. But from Gilead’s perspective, as Nate Gregory noted in an article on Briefs Finance, this ruling is about patient protection. It's about ensuring that drugs entering the U.S. aren't skirting FDA oversight, potentially introducing substandard, adulterated, or even counterfeit medicine into our healthcare system. Shabbir Imber Safdar, Executive Director of the Partnership for Safe Medicines, has been vocal about these very concerns for a while, highlighting the dangers.

Now, what does this mean for the future of Alternative Funding Programs? While the ruling is expected to significantly impact, and perhaps shrink, the AFP industry, it's important to understand it doesn't "kill the AFP industry instantly." It's a powerful blow, certainly, reinforcing the idea that drug importation through these unregulated pathways carries substantial legal risk. The full ramifications on market participants and patient access to potentially lower-cost drugs are still unfolding, but one thing is clear: the appeals court has drawn a very firm line in the sand regarding the integrity of our pharmaceutical supply chain.